本帖最后由 老马 于 2012-1-13 21:20 编辑
, @, R7 N0 A' d! W- p9 g" r @3 J% \( e- `# j0 t/ M: w
爱必妥和阿瓦斯丁的比较, j, M; Q. B0 P( Q# V" d5 x9 [
4 ?' Q3 H- J/ h
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
+ o+ W7 Q3 \$ B8 Y) Q' `2 x
+ h& i6 }; Z/ L( I! c
4 j9 K+ x0 b+ xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/" C" C4 Q6 B2 [1 p0 d
==================================================
) e3 m0 |- @; I/ f3 J5 hOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
1 l& ~' D$ h4 N2 F3 d1 F7 `. X0 G5 k KPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
; v; l# g* L1 a, n! Z4 k: n! dResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% |$ T! L+ K* ]( y; b, |$ S; H
|